Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for Symptomatic Cerebral Arteriovenous Malformations
NCT06264531Phase 3Recruiting
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised trial in cerebral arteriovenous malformation (AVM) comparing Bevacizumab with Placebo (2 arms). Primary endpoint: Proportion of patients showing improvement in cognition, neurological symptoms, epilepsy symptoms, or headaches at 6 months. Started Jan 2026; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
cerebral arteriovenous malformation (AVM)
Beyond the preview
Go deeper on NCT06264531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06264531.